- call +1-201-465-4211
- email sales@mrinsights.biz
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
Scope of the Report:
This report studies the Antisense & RNAi Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Antisense & RNAi Therapeutics market by product type and applications/end industries.
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.
The global Antisense & RNAi Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Antisense & RNAi Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
RNA interference
SiRNA
MiRNA
Antisense RNA
Market Segment by Applications, can be divided into
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Antisense & RNAi Therapeutics Market Overview
1.1 Product Overview and Scope of Antisense & RNAi Therapeutics
1.2 Classification of Antisense & RNAi Therapeutics by Types
1.2.1 Global Antisense & RNAi Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Types in 2017
1.2.3 RNA interference
1.2.4 SiRNA
1.2.5 MiRNA
1.2.6 Antisense RNA
1.3 Global Antisense & RNAi Therapeutics Market by Application
1.3.1 Global Antisense & RNAi Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Oncology
1.3.3 Cardiovascular
1.3.4 Renal
1.3.5 Neurodegenerative
1.3.6 Respiratory
1.3.7 Genetic
1.3.8 Infectious Diseases
1.4 Global Antisense & RNAi Therapeutics Market by Regions
1.4.1 Global Antisense & RNAi Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Antisense & RNAi Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Antisense & RNAi Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Antisense & RNAi Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Antisense & RNAi Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Antisense & RNAi Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Antisense & RNAi Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Glaxo Smith Kline
2.1.1 Business Overview
2.1.2 Antisense & RNAi Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi Aventis / Genzyme
2.2.1 Business Overview
2.2.2 Antisense & RNAi Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
2.3.1 Business Overview
2.3.2 Antisense & RNAi Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Arbutus Biopharma Ltd.
2.4.1 Business Overview
2.4.2 Antisense & RNAi Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Silence Therapeutics
2.5.1 Business Overview
2.5.2 Antisense & RNAi Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bio-Path Holdings Inc.
2.6.1 Business Overview
2.6.2 Antisense & RNAi Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Calando Pharmaceuticals
2.7.1 Business Overview
2.7.2 Antisense & RNAi Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 ICo Therapeutics
2.8.1 Business Overview
2.8.2 Antisense & RNAi Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Quark Pharmaceuticals
2.9.1 Business Overview
2.9.2 Antisense & RNAi Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Rexhan Pharmaceuticals
2.10.1 Business Overview
2.10.2 Antisense & RNAi Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Biomarin/Prosensa
2.11.1 Business Overview
2.11.2 Antisense & RNAi Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 Regulus Therapeutics
2.12.1 Business Overview
2.12.2 Antisense & RNAi Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Rxi Pharmaceuticals
2.13.1 Business Overview
2.13.2 Antisense & RNAi Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 Silenseed
2.14.1 Business Overview
2.14.2 Antisense & RNAi Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Silenseed Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.15 Dicerna Pharmaceuticals
2.15.1 Business Overview
2.15.2 Antisense & RNAi Therapeutics Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.16 Sirnaomics Inc.
2.16.1 Business Overview
2.16.2 Antisense & RNAi Therapeutics Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Antisense & RNAi Therapeutics Market Competition, by Players
3.1 Global Antisense & RNAi Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Antisense & RNAi Therapeutics Players Market Share
3.2.2 Top 10 Antisense & RNAi Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Antisense & RNAi Therapeutics Market Size by Regions
4.1 Global Antisense & RNAi Therapeutics Revenue and Market Share by Regions
4.2 North America Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Antisense & RNAi Therapeutics Revenue by Countries
5.1 North America Antisense & RNAi Therapeutics Revenue by Countries (2013-2018)
5.2 USA Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Antisense & RNAi Therapeutics Revenue by Countries
6.1 Europe Antisense & RNAi Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Antisense & RNAi Therapeutics Revenue by Countries
7.1 Asia-Pacific Antisense & RNAi Therapeutics Revenue by Countries (2013-2018)
7.2 China Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Antisense & RNAi Therapeutics Revenue by Countries
8.1 South America Antisense & RNAi Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Antisense & RNAi Therapeutics by Countries
9.1 Middle East and Africa Antisense & RNAi Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Antisense & RNAi Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Antisense & RNAi Therapeutics Market Segment by Type
10.1 Global Antisense & RNAi Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Antisense & RNAi Therapeutics Market Forecast by Type (2018-2023)
10.3 RNA interference Revenue Growth Rate (2013-2023)
10.4 SiRNA Revenue Growth Rate (2013-2023)
10.5 MiRNA Revenue Growth Rate (2013-2023)
10.6 Antisense RNA Revenue Growth Rate (2013-2023)
11 Global Antisense & RNAi Therapeutics Market Segment by Application
11.1 Global Antisense & RNAi Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Antisense & RNAi Therapeutics Market Forecast by Application (2018-2023)
11.3 Oncology Revenue Growth (2013-2018)
11.4 Cardiovascular Revenue Growth (2013-2018)
11.5 Renal Revenue Growth (2013-2018)
11.6 Neurodegenerative Revenue Growth (2013-2018)
11.7 Respiratory Revenue Growth (2013-2018)
11.8 Genetic Revenue Growth (2013-2018)
11.9 Infectious Diseases Revenue Growth (2013-2018)
12 Global Antisense & RNAi Therapeutics Market Size Forecast (2018-2023)
12.1 Global Antisense & RNAi Therapeutics Market Size Forecast (2018-2023)
12.2 Global Antisense & RNAi Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Antisense & RNAi Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Antisense & RNAi Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Antisense & RNAi Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Antisense & RNAi Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Antisense & RNAi Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Antisense & RNAi Therapeutics Picture
Table Product Specifications of Antisense & RNAi Therapeutics
Table Global Antisense & RNAi Therapeutics and Revenue (Million U
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
